| 000 | 01743 a2200457 4500 | ||
|---|---|---|---|
| 005 | 20250518052338.0 | ||
| 264 | 0 | _c20200204 | |
| 008 | 202002s 0 0 eng d | ||
| 022 | _a1950-6007 | ||
| 024 | 7 |
_a10.1016/j.biopha.2019.109245 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aGupta, Preeti | |
| 245 | 0 | 0 |
_aEvaluation of ellagic acid as an inhibitor of sphingosine kinase 1: A targeted approach towards anticancer therapy. _h[electronic resource] |
| 260 |
_bBiomedicine & pharmacotherapy = Biomedecine & pharmacotherapie _cOct 2019 |
||
| 300 |
_a109245 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article | ||
| 650 | 0 | 4 | _aA549 Cells |
| 650 | 0 | 4 |
_aAntineoplastic Agents _xpharmacology |
| 650 | 0 | 4 |
_aCell Death _xdrug effects |
| 650 | 0 | 4 |
_aCell Proliferation _xdrug effects |
| 650 | 0 | 4 |
_aEllagic Acid _xchemistry |
| 650 | 0 | 4 | _aHEK293 Cells |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aMolecular Docking Simulation |
| 650 | 0 | 4 | _aMolecular Targeted Therapy |
| 650 | 0 | 4 |
_aPhosphotransferases (Alcohol Group Acceptor) _xantagonists & inhibitors |
| 650 | 0 | 4 | _aPrincipal Component Analysis |
| 650 | 0 | 4 |
_aProtein Kinase Inhibitors _xpharmacology |
| 650 | 0 | 4 | _aProtein Structure, Secondary |
| 650 | 0 | 4 |
_aRecombinant Proteins _xisolation & purification |
| 650 | 0 | 4 | _aSpectrometry, Fluorescence |
| 650 | 0 | 4 | _aThermodynamics |
| 700 | 1 | _aMohammad, Taj | |
| 700 | 1 | _aKhan, Parvez | |
| 700 | 1 | _aAlajmi, Mohamed F | |
| 700 | 1 | _aHussain, Afzal | |
| 700 | 1 | _aRehman, Md Tabish | |
| 700 | 1 | _aHassan, Md Imtaiyaz | |
| 773 | 0 |
_tBiomedicine & pharmacotherapy = Biomedecine & pharmacotherapie _gvol. 118 _gp. 109245 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1016/j.biopha.2019.109245 _zAvailable from publisher's website |
| 999 |
_c29946511 _d29946511 |
||